Please ensure Javascript is enabled for purposes of website accessibility

Will Worse Side Effects for Moderna's Vaccine Boost Pfizer's Fortunes?

By Keith Speights - Apr 13, 2021 at 5:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's possible.

Three COVID-19 vaccines are currently available to Americans. One of them, however, faces some challenges. Johnson & Johnson won't be able to supply as many doses of its vaccine in the next few weeks as originally hoped due to manufacturing issues at a contractor's facility. Questions about whether the vaccine could cause blood clots on a very rare basis have also arisen. 

With these headwinds for J&J, the vaccines developed by Moderna (MRNA 2.58%) and Pfizer (PFE 2.15%) (with its partner BioNTech (BNTX -0.52%)) are in high demand. Both vaccines have very high efficacy levels. Both Moderna and Pfizer/BioNTech have secured supply deals with the U.S. for 300 million doses each.

But new research findings appear to indicate that individuals who receive Moderna's vaccine are more likely to experience reactions and side effects. Could this latest news boost Pfizer's fortunes?

Woman wearing a face mask looking back at a healthcare professional as he gives her a shot in the arm.

Image source: Getty Images.

More side effects for Moderna

Both Pfizer's and Moderna's COVID-19 vaccines use the same approach. Messenger RNA (mRNA) is injected into the body. This mRNA contains instructions for producing proteins that are identical to the spike protein on the surface of SARS-CoV-2, the coronavirus that causes COVID-19. The body then develops antibodies and T cells that can fight the virus in the future, thereby providing protection against infection.

Because the two vaccines use this same approach, similar side effects were reported in clinical studies conducted by Moderna and Pfizer/BioNTech. The most frequent reactions included pain at injection sites, fatigue, and headache. 

The U.S. Centers for Disease Control and Prevention (CDC) has tracked data about adverse reactions for both vaccines in the agency's V-safe surveillance system. Last week, CDC scientists published an article in the online medical journal JAMA that analyzed the V-safe data recorded between Dec. 14, 2020, and Feb. 28, 2021.

This analysis showed that 73.9% of respondents in the V-safe system experienced side effects after taking the first dose of Moderna's COVID-19 vaccine. The number was lower -- 65.4% -- for individuals receiving the first dose of Pfizer's vaccine.

It was a similar story after the second dose of each vaccine. Among respondents receiving Moderna's shot, 81.9% reported experiencing side effects. For those receiving the Pfizer vaccine, 68.6% reported a reaction after the second dose.

A positive effect for Pfizer?

Pfizer has already reported slightly higher efficacy for its COVID-19 vaccine than Moderna. Is the data showing that its vaccine produces fewer side effects potentially good news for the big pharma stock? Maybe.

The U.S. already has more than enough COVID-19 vaccine doses ordered to vaccinate all Americans this year. Several other developed nations have also made large supply deals with various vaccine makers. It's possible that Pfizer could receive more orders as a result of the competitive advantages of its vaccine compared to Moderna's vaccine. However, the short-term impact for Pfizer's share price would likely be relatively small.

It could be a different story over the longer term, though. When countries aren't forced to scramble to secure vaccine doses, they could (and probably will) place greater emphasis on the efficacy and safety profiles of the vaccines they buy. That just might give Pfizer a leg up over Moderna.

A relatively modest 10% increase in doses ordered each year could translate to well over $1 billion for Pfizer. Even after splitting its profits with BioNTech, the big drugmaker would stand to rake in a lot more money if it can beat Moderna in the post-pandemic marketplace.

Changing dynamics

Don't get the cart before the horse, however. There are far too many changing dynamics in the COVID-19 vaccine space that could offset any advantage that Pfizer might have related to the latest CDC data.

Probably the most important to keep in mind is the emergence of new variants. Pfizer and BioNTech have begun testing a third booster dose of their COVID-19 vaccine. Moderna is testing a modified version of its mRNA vaccine that specifically targets the B.1.351 variant first identified in South Africa. 

Moderna's vaccine could demonstrate significantly greater efficacy against the South African variant than Pfizer's vaccine. If that happens, a slightly lower chance of adverse reactions likely wouldn't help Pfizer compete against Moderna. There's also the possibility that another COVID-19 vaccine could win authorization or approval down the road that's even more safe and effective than Pfizer's or Moderna's vaccines.  

Still, the good news keeps coming for Pfizer's COVID-19 vaccine. This could cumulatively boost investors' confidence in the stock. That's a side effect that Pfizer would love to see.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.75 (2.15%) $1.11
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.30 (0.09%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$159.56 (2.58%) $4.02
BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.20 (-0.52%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.